Ropivacaine ER is a small molecule commercialized by PainReform, with a leading Phase III program in Post-Operative Pain. According to Globaldata, it is involved in 4 clinical trials, of which 2 were completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Ropivacaine ER’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Ropivacaine ER is expected to reach an annual total of $44 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Ropivacaine ER Overview
Ropivacaine ER (PRF-110) is under development for the treatment of post-operative pain in hallux valgus (Bunion) surgery. The drug candidate is an extended-release viscous solution formulation delivered through a sterile, prefilled syringe into the surgical wound developed based on generally regarded as safe (GRAS) excipients platform. It is administered parenterally and acts by targeting sodium channel.
PainReform Overview
PainReform is a pharmaceutical company that offers products for the treatment and management of pain. It focuses on the reformulation of established therapeutics. The company offers PRF-110, a generic local analgesic drug that provides a prolonged action of the local anesthetic ropivacaine and nonsteroidal anti-inflammatory drugs. PainReform specializes in pain drug development to structure creative clinical trials and advances products through clinical proof of concepts, regulatory approval and commercialization. The company also investigates PRF-110 program for postsurgical pain relief. PainReform is headquartered in Herzeliya, Israel.
The operating loss of the company was US$8.9 million in FY2022, compared to an operating loss of US$7.2 million in FY2021. The net loss of the company was US$8.8 million in FY2022, compared to a net loss of US$7.3 million in FY2021.
For a complete picture of Ropivacaine ER’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
